Repros Therapeutics (RPRX) Provides Update for Proellex Clinical Program
More News related to RPRX
- Repros Therapeutics Announces Settlement with Major Creditors
- Repros Therapeutics Announces Amendment of NIH Proellex(R) License
- Unusual 11 Mid-Day Movers 10/09: SCIL, SRZ, CAGC, IVAN Higher; ACOR, SPPI, LXRX, UCBH Lower
- Unusual 11 Mid-Day Movers 10/08: CLWT, LIZ, XRM, NCT Higher; RPRX, STC, SVNT, TLR Lower
- Morning Movers 10/08: RPC, NCT, TLF, LIZ, DDSS Higher; CTZN, RPRX, STC, TLR, VG, SVNT Lower
Repros Therapeutics (Nasdaq: RPRX) announced today that an end of Phase II meeting is scheduled with the FDA for late September 2009 to discuss a Phase III program investigating the use of Proellex in the treatment of endometriosis.
The Phase II study that Repros completed earlier this year demonstrated clinically and statistically significant reductions of the three key pain symptoms commonly experienced by women with endometriosis: dysmenorrhea (painful menses), non-menstrual pelvic pain, and dyspareunia (painful intercourse). Additionally, the reduction of pain was accompanied by a statistically significant reduction in the number of patients requiring pain medication in both doses in this Phase II study compared with placebo. The study showed no efficacy differences between the 25 mg and 50 mg doses.
Subscribe to EasyStockAlerts.com & Get real-time e-mail alerts when news hits your stocks!
Related Categories
Corporate NewsFDA
Stocks Mentioned
-0.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
